Investigational drug · Phase 3
Ivonescimab
Also called: AK112, SMT112
Not approved by FDA. In 49 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
49
47 still active
All registered trials
134
Any phase or sponsor naming "Ivonescimab"
First trial start
2021
Feb 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Akeso36
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ivonescimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Advanced Malignant Tumors
- Advanced Solid Tumors
- Non-Squamous Non-small Cell Lung Cancer
- Advanced Non-small-cell Lung Cancer
- Biliary Tract Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Ivonescimab" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsPivotal-lookingActive, not recruiting
Summit TherapeuticsIndustry
NCT05899608 · 1,600 participants (planned) · Start Oct 26, 2023 · Primary completion Dec 31, 2028
Drug: Ivonescimab Injection; Pembrolizumab Injection · For: Non-Small Cell Lung Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 260 sites in all
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPivotal-lookingRecruiting
AkesoIndustry
NCT06953999 · 999 participants (planned) · Start Jun 11, 2025 · Primary completion May 14, 2027
Drug: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine; Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine and 1 more · For: Pancreatic Cancer
Sites: Harbin, China; Shanghai, China; Hangzhou, China
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPivotal-lookingRecruiting
Summit TherapeuticsIndustry
NCT07228832 · 900 participants (planned) · Start Nov 18, 2025 · Primary completion May 31, 2028
Drug: Drug: Ivonescimab Injection; Drug: Bevacizumab Injection · For: Metastatic Colorectal Cancer (CRC)
Sites: Mobile, Alabama; Tuscaloosa, Alabama; Goodyear, Arizona · 243 sites in all
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaPivotal-lookingRecruiting
Summit TherapeuticsIndustry
NCT07815665 · 800 participants (planned) · Start Sep 10, 2026 · Primary completion Oct 31, 2030
Drug: Ivonescimab Dose 1; enfortumab vedotin (EV) and 3 more · For: Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 7 sites in all
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Pivotal-lookingRecruiting
Summit TherapeuticsIndustry
NCT06767514 · 780 participants (planned) · Start Feb 27, 2025 · Primary completion Apr 2028
Drug: Ivonescimab Injection; Pembrolizumab Injection · For: Non-Small Cell Lung Cancer
Sites: Chandler, Arizona; Phoenix, Arizona; Hot Springs, Arkansas · 292 sites in all
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNPivotal-lookingRecruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT07264075 · 780 participants (planned) · Start May 5, 2026 · Primary completion May 2030
Drug: Ivonescimab 10 mg/kg; Ligufalimab and 1 more · For: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Sites: Le Havre, France
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyPivotal-lookingRecruiting
AkesoIndustry
NCT07010263 · 560 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 31, 2028
Drug: AK112 · For: Small Cell Lung Cancer
Sites: Beijing, China; Beijin, China; Chongqing, China · 53 sites in all
- Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerPivotal-lookingRecruiting
AkesoIndustry
NCT06928389 · 536 participants (planned) · Start Jul 8, 2025 · Primary completion May 2027
Drug: Ivonescimab, docetaxel; Placebo, docetaxel · For: Non-Small Cell Lung Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review.
Xu M, Qiu S, Zhou J, et al. · Hum Vaccin Immunother 2026
- Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.
Zhao X, Zhang B, Li C, et al. · Nat Med 2026
- Phase III Trials Test First-Line Options in Advanced NSCLC.
· Cancer Discov 2026
- Ivonescimab combined with radiotherapy in the treatment of advanced lung adenocarcinoma with high expression of PD-L1: A case report.
Zhou Q, Yang B, Cai H, et al. · Oncol Lett 2026
- Stage IIIB pulmonary sarcomatoid carcinoma treated with spatially fractionated radiotherapy combined with antiangiogenic therapy and sequential chemo-immunotherapy: A case report.
Qiu Z, Xuan F, Mao X, et al. · Oncol Lett 2026
- Recent advances and future challenges of bispecific antibodies in lung cancer.
Du M, Han Y, Jin R, et al. · Crit Rev Oncol Hematol 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.